RT Journal Article
T1 Incidence, clinical, risk factors and outcomes of Guillain-Barré in Covid-19.
A1 Fragiel, Marcos
A1 Miro, Oscar
A1 Llorens, Pere
A1 Jimenez, Sonia
A1 Piñera, Pascual
A1 Burillo, Guillermo
A1 Martin, Alfonso
A1 Martin-Sanchez, Francisco J
A1 Garcia-Lamberechts, Eric J
A1 Jacob, Javier
A1 Alquezar-Arbe, Aitor
A1 Juarez, Ricardo
A1 Jimenez, Blas
A1 Del Rio, Rigoberto
A1 Mateo Roca, Miriam
A1 Garcia, Arturo H
A1 Lopez Laguna, Nieves
A1 Lopez Diez, Maria P
A1 Pedraza Garcia, Jorge
A1 Fernandez de Simon Almela, Amparo
A1 Lopez Diaz, Juan J
A1 Eiroa Hernandez, Patricia
A1 Ruiz de Lobera, Noemi
A1 Porta-Etessam, Jesus
A1 Fernandez Perez, Cristina
A1 Calvo, Elpidio
A1 Gonzalez Del Castillo, Juan
K1 Adult
K1 Aged
K1 COVID-19
K1 Case-Control Studies
K1 Female
K1 Guillain-Barre Syndrome
K1 Hospital Mortality
K1 Humans
AB We diagnosed 11 Guillain-Barré syndrome (GBS) cases among 71,904 COVID patients attended at 61 Spanish emergency departments (EDs) during the 2-month pandemic peak. The relative frequency of GBS among ED patients was higher in COVID (0.15‰) than non-COVID (0.02‰) patients (odds ratio [OR] = 6.30, 95% confidence interval [CI] = 3.18-12.5), as was the standardized incidence (9.44 and 0.69 cases/100,000 inhabitant-years, respectively, OR = 13.5, 95% CI = 9.87-18.4). Regarding clinical characteristics, olfactory-gustatory disorders were more frequent in COVID-GBS than non-COVID-GBS (OR = 27.59, 95% CI = 1.296-587) and COVID-non-GBS (OR = 7.875, 95% CI = 1.587-39.09) patients. Although COVID-GBS patients were more frequently admitted to intensive care, mortality was not increased versus control groups. Our results suggest SARS-CoV-2 could be another viral infection causing GBS. ANN NEUROL 2021;89:598-603.
PB John Wiley & Sons, Inc.
YR 2020
FD 2020-12-09
LK http://hdl.handle.net/10668/16761
UL http://hdl.handle.net/10668/16761
LA en
NO Fragiel M, Miró Ò, Llorens P, Jiménez S, Piñera P, Burillo G, et al.  Incidence, clinical, risk factors and outcomes of Guillain-Barré in Covid-19. Ann Neurol. 2021 Mar;89(3):598-603.
DS RISalud
RD Apr 6, 2025